NCT05075538

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 152 (actual)
• Sponsor: Jules Bordet Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.

Conditions

• Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Spikevax	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Comirnaty	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Spikevax bivalent Original/Omicron BA.1	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Spikevax bivalent Original/Omicron BA.4-5	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Comirnaty Original/Omicron BA.1	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Comirnaty Original/Omicron BA.4-5	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Comirnaty Omicron XBB.1.5	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
BIOLOGICAL	Spikevax Omicron XBB.1.5	Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.

Timeline

• Start date: 2021-12-01
• Primary completion: 2024-01-08
• Completion: 2024-01-08
• First posted: 2021-10-12
• Last updated: 2024-01-17

Locations

2 sites across 1 country: Belgium